Advertisement

Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia

Data recently published from the phase III PERSIST-2 trial shows that the oral JAK2/FLT inhibitor pacritinib demonstrates a higher reduction in spleen volume and in total symptom score in patients with myelofibrosis and thrombocytopenia compared with best available therapy.

 Cancer Network